An Observational Study to Assess Persistence, Adherence, Quality of Life, and Treatment Satisfaction in Patients Beginning Therapy With the Avonex PEN
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2015
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PERSIST
- Sponsors Biogen Idec
- 08 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 May 2014 Preliminary 12-month results presented at the 66th Annual Meeting of the American Academy of Neurology.
- 13 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.